Effects of access barriers and medication acceptability on buprenorphine-naloxone treatment utilization over 2 years: Results from a multisite randomized trial of adults with opioid use disorder

被引:23
作者
Evans, Elizabeth A. [1 ]
Yoo, Caroline [2 ]
Huang, David [2 ]
Saxon, Andrew J. [3 ]
Hser, Yih-Ing [2 ]
机构
[1] Univ Massachusetts, Sch Publ Hlth & Hlth Sci, Dept Hlth Promot & Policy, 312 Arnold House,715 North Pleasant St, Amherst, MA 01003 USA
[2] Univ Calif Los Angeles, Integrated Subst Abuse Programs, Semel Inst Neurosci & Human Behav, 11075 Santa Monica Blvd,Ste 200, Los Angeles, CA 90024 USA
[3] Vet Affairs Puget Sound Hlth Care Syst, 1660 S Columbian Way, Seattle, WA 98108 USA
关键词
Buprenorphine; Treatment acceptability; access; and utilization; Opioid use disorder; Pharmacotherapy; Longitudinal; MAINTENANCE TREATMENT; PATIENT PERSPECTIVES; METHADONE TREATMENT; ADDICTION; DEPENDENCE; RETENTION; OUTCOMES; MORTALITY; ABUSE; FACILITIES;
D O I
10.1016/j.jsat.2019.08.002
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Background: Nationwide efforts seek to address the opioid epidemic by increasing access to medications for opioid use disorder (OUD), particularly with buprenorphine. A poorly understood challenge is that among individuals with OUD who do receive buprenorphine, many do not adhere to the pharmacotherapy long enough to achieve sustained benefits. We aimed to identify factors associated with buprenorphine treatment utilization over time. Methods: We used random-intercept modeling to identify factors associated with buprenorphine treatment utilization over 2 years after first follow-up by 789 individuals with OUD who had participated in a multi-site randomized clinical trial of buprenorphine compared to methadone. Key predictors were participants' reports of buprenorphine treatment accessibility and acceptability (assessed at first follow-up) and their interaction effects, controlling for baseline randomization status, sociodemographics, and other covariates. Results: Approximately 9.3-11.2% of participants utilized buprenorphine treatment over the 2 years of follow-up. Interaction effects indicated that individuals who perceived buprenorphine to be both accessible and acceptable were most likely to use buprenorphine during follow-up, controlling for other factors. In contrast, individuals who perceived buprenorphine to be unacceptable were least likely to use buprenorphine, regardless the level of perceived access to the medication. Buprenorphine treatment utilization was also negatively associated with Hispanic ethnicity, West coast context, and cumulative months receiving methadone treatment and incarceration during follow-up. Conclusions: To engage more individuals with OUD in long-term treatment with buprenorphine, interventions should target buprenorphine treatment acceptability, in addition to increasing buprenorphine access, and tailor efforts to meet the needs of vulnerable populations.
引用
收藏
页码:19 / 28
页数:10
相关论文
共 46 条
[11]   Criminal justice outcomes over 5 years after randomization to buprenorphine-naloxone or methadone treatment for opioid use disorder [J].
Evans, Elizabeth A. ;
Zhu, Yuhui ;
Yoo, Caroline ;
Huang, David ;
Hser, Yih-Ing .
ADDICTION, 2019, 114 (08) :1396-1404
[12]   A Comparison of Characteristics and Outcomes of Opioid-Dependent Patients Initiating Office-Based Buprenorphine or Methadone Maintenance Treatment [J].
Fingerhood, Michael I. ;
King, Van L. ;
Brooner, Robert K. ;
Rastegar, Darius A. .
SUBSTANCE ABUSE, 2014, 35 (02) :122-126
[13]   Patient Perspectives on Choosing Buprenorphine Over Methadone in an Urban, Equal-Access System [J].
Gryczynski, Jan ;
Jaffe, Jerome H. ;
Schwartz, Robert P. ;
Dusek, Kristi A. ;
Gugsa, Nishan ;
Monroe, Cristin L. ;
O'Grady, Kevin E. ;
Olsen, Yngvild K. ;
Mitchell, Shannon Gwin .
AMERICAN JOURNAL ON ADDICTIONS, 2013, 22 (03) :285-291
[14]   Integrating buprenorphine maintenance therapy into federally qualified health centers: Real-world substance abuse treatment outcomes [J].
Haddad, Marwan S. ;
Zelenev, Alexei ;
Altice, Frederick L. .
DRUG AND ALCOHOL DEPENDENCE, 2013, 131 (1-2) :127-135
[15]   WHAT ARE THE POLICY IMPLICATIONS OF THE EVIDENCE ON CANNABIS USE AND PSYCHOSIS? [J].
Hall, Wayne ;
Degenhardt, Louisa .
ADDICTION, 2010, 105 (08) :1332-1333
[16]  
Hedegaard Holly, 2017, NCHS Data Brief, P1, DOI 10.15620/cdc:101761
[17]  
Hser Y., 1992, PSYCHOL ASSESSMENT, V4, P207, DOI [DOI 10.1037//1040-3590.4.2.207, DOI 10.1037/1040-3590.4.2.207]
[18]   The life course perspective on drug use - A conceptual framework for understanding drug use trajectories [J].
Hser, Yih-Ing ;
Longshore, Douglas ;
Anglin, M. Douglas .
EVALUATION REVIEW, 2007, 31 (06) :515-547
[19]   Distinctive Trajectories of Opioid Use Over an Extended Follow-up of Patients in a Multisite Trial on Buprenorphine plus Naloxone and Methadone [J].
Hser, Yih-Ing ;
Huang, David ;
Saxon, Andrew J. ;
Woody, George ;
Moskowitz, Andrew L. ;
Matthews, Abigail G. ;
Ling, Walter .
JOURNAL OF ADDICTION MEDICINE, 2017, 11 (01) :63-69
[20]   Long-term outcomes after randomization to buprenorphine/naloxone versus methadone in a multi-site trial [J].
Hser, Yih-Ing ;
Evans, Elizabeth ;
Huang, David ;
Weiss, Robert ;
Saxon, Andrew ;
Carroll, Kathleen M. ;
Woody, George ;
Liu, David ;
Wakim, Paul ;
Matthews, Abigail G. ;
Hatch-Maillette, Mary ;
Jelstrom, Eve ;
Wiest, Katharina ;
McLaughlin, Paul ;
Ling, Walter .
ADDICTION, 2016, 111 (04) :695-705